ClearPoint Neuro, Inc. (CLPT) Stock Price & Analysis
ClearPoint Neuro, Inc. (CLPT) — MoonshotScore 16/100 (Weak band), calculated Nov 18, 2026. Price $6.91 (-5.47%), as of the Nov 20, 2026 trading session; market cap $221M.
Educational signal · not a buy or sell recommendation · How to read this
ClearPoint Neuro, Inc. · CLPT · NASDAQ
ClearPoint Neuro, Inc. is a medical device company specializing in platforms for minimally invasive surgical procedures in the brain under MRI guidance. Their products include the ClearPoint system and ClearPoint Neuro Navigation System, aiming to improve precision and outcomes in neurosurgery.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · ClearPoint Neuro (CLPT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and weak growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Fading; Momentum: Slipping.
- quarterly revenue $12M (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 1 of the last 8 reports
- Altman Z -1.18 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 16 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 16 | Weak | |
| 16 | Weak | |
| 16 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.91 | |
| Change on the day | -5.47% | |
| 52-week range | $6.91 – $19.63 | |
| Market capitalisation | $221M | — |
| Price / earnings (trailing) | -14.47 | |
| Shares traded on the day | 1.11M |
Price & events
Other perspectives
Council score for ClearPoint Neuro (CLPT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is ClearPoint Neuro (CLPT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ClearPoint Neuro, Inc. (CLPT) is listed on NASDAQ. It employs 172 people and is led by Joseph Michael Burnett. In Q3 FY2026 it reported revenue of $12M and net income of -$7M. The market values it at $221M.
What do the latest results show for ClearPoint Neuro (CLPT)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $12M. Against analyst estimates the company has EPS beat 1 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $12M | -$7M | -$0.24 (diluted) |
| Q2 FY2026 | $11M | -$11M | -$0.38 (diluted) |
| Q1 FY2026 | $12M | -$10M | -$0.32 (diluted) |
| Q4 FY2025 | $10M | -$8M | -$0.27 (diluted) |
What are the financial strengths and risks for ClearPoint Neuro (CLPT)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z -1.18 · Piotroski F 2. Trailing ratios: ROA -32.1% · current ratio 6.76 · earnings yield -13.8% · free-cash-flow yield -12.2%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -1.18 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at ClearPoint Neuro (CLPT)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does ClearPoint Neuro compare with its peers?
Short answer
ClearPoint Neuro's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $18.79 Nov 20, 2026 | $654M | 94 5-pillar Nov 18, 2026 | |
| $25.60 Nov 20, 2026 | $573M | 90 5-pillar Nov 18, 2026 | |
| $8.52 Nov 20, 2026 | $323M | 88 5-pillar Nov 18, 2026 | |
| $22.98 Nov 20, 2026 | $188M | 87 5-pillar Nov 18, 2026 | |
| $8.73 Nov 19, 2026 | $351M | 87 5-pillar Nov 18, 2026 | |
| $41.98 Nov 20, 2026 | $60.9B | 77 5-pillar Nov 18, 2026 | |
| $13.23 Nov 20, 2026 | $177M | 71 5-pillar Nov 18, 2026 | |
| $1.49 Nov 20, 2026 | $93.7M | 43 5-pillar Nov 18, 2026 | |
| $3.23 Nov 19, 2026 | $96.5M | 41 5-pillar Nov 18, 2026 | |
| $5.30 Nov 20, 2026 | $138M | 37 5-pillar Nov 18, 2026 | |
| $6.07 Nov 20, 2026 | $247M | 36 5-pillar Nov 18, 2026 | |
| $8.67 Nov 20, 2026 | $361M | 35 5-pillar Nov 18, 2026 | |
| ClearPoint Neuro (CLPT) — this page | $6.91 | $221M | 16 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $18.00 – $25.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $21.50
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $21.50
Historical target record · Captured · Capture expired; not a current watchpoint.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CLPT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CLPT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ClearPoint Neuro (CLPT)?
What Investors Ask About ClearPoint Neuro (CLPT)
These answers are editorial: 1 of these 9 answers is drawn from the CLPT research dossier (written May 6, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for CLPT?
CLPT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is CLPT a good stock to buy?
Stock Expert AI does not rate CLPT buy, sell or hold. ClearPoint Neuro, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the CLPT stock price today?
The last price recorded for ClearPoint Neuro, Inc. (CLPT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CLPT price target?
The last analyst consensus price target we captured for ClearPoint Neuro, Inc. (CLPT), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What do analysts say about CLPT stock?
Analyst coverage of ClearPoint Neuro, Inc. focuses on the company's growth potential in the neurosurgical device market. Key valuation metrics include revenue growth, gross margin, and market capitalization. However, the company's negative profit margin and limited market share are areas of concern.
What are the key factors to evaluate for CLPT?
ClearPoint Neuro, Inc. (CLPT) holds a MoonshotScore in the low range. These partnerships can provide access to new technologies, expertise, and distribution channels. Not financial advice.
How frequently does CLPT data refresh on this page?
CLPT's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven CLPT's recent stock price performance?
ClearPoint Neuro, Inc. (CLPT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative MRI-guided platform for precise neurosurgery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLPT overvalued or undervalued right now?
ClearPoint Neuro, Inc. (CLPT) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 6, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com